automated-platform

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 62/100

   Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform

   ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Nature medicine · 2025-04-09 · Biomarkers

   Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests.

   • Biomarkers
2. 57/100

   Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform

   ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's research & therapy · 2025-03-27 · Biomarkers

   Plasma p-tau217 shows excellent results for detecting amyloid pathology at brain level in a clinical setting with an AUC of 0.95.

   • Biomarkers
   • Diagnosis
3. 48/100

   Blood biomarkers for Alzheimer's disease with the Lumipulse automated platform: Age-effect and clinical value interpretation

   ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Clinica chimica acta; international journal of clinical chemistry · 2024-10-22 · Biomarkers

   The specific context of use might be considered to define the cut-offs of blood biomarkers of neurodegenerative diseases.

   • Biomarkers
4. 45/100

   Evaluation of core Biomarkers of Alzheimer's disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Scientific reports · 2024-07-12 · Biomarkers

   Cerebrospinal fluid (CSF) core biomarkers of Alzheimer's disease (AD), including amyloid peptide beta-42 (Aβ42), Aβ42/40 ratio, and phosphorylated tau (pTau), are precious tools for supporting AD diagnosis.

   • Biomarkers
5. 47/100

   Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform

   ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer's research & therapy · 2023-10-02 · Biomarkers

   Plasma biomarkers of AD using the automated Lumipulse platform show good diagnostic performance in detecting Alzheimer's pathology in cognitively unimpaired subjects.

   • Biomarkers
   • Diagnosis
   • Early Stage
6. 50/100

   Influence of kidney function and CSF/serum albumin ratio on plasma Aβ42 and Aβ40 levels measured on a fully automated platform in patients with Alzheimer's disease

   ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023-06-07 · Biomarkers

   Plasma Aβ42 and Aβ40 are critically influenced by kidney function; however, their ratio is advantageously spared from this effect.

   • Biomarkers
7. 55/100

   Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest

   ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Frontiers in aging neuroscience · 2021-03-04 · Biomarkers

   Manual ELISA assays are the most commonly used methods for quantification of biomarkers; however, they often show inter- and intra-laboratory variability that limits their wide use.

   • Biomarkers
   • Diagnosis

All topic tags with their study counts